Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561523 | 1.00 | AKR1C3 (0.58) | AKR1C3KMT2AMEN1POLBESR1 | |
| SCHEMBL3187597 | 0.94 | ESR1 (0.61) | AKR1C3KMT2AMEN1POLBESR1 | |
| SCHEMBL2061544 | 0.91 | ALDH1A1 (0.56) | AKR1C3KMT2AMEN1POLBESR1 | |
| SCHEMBL22898424 | 0.88 | LMNA (0.51) | AKR1C3KMT2AMEN1POLBESR1 | |
| SCHEMBL29558059 | 0.80 | ADRA2A (0.51) | AKR1C3KMT2AMEN1POLBLMNA | |
| SCHEMBL324724 | 0.80 | ADRA2A (0.51) | AKR1C3KMT2AMEN1POLBLMNA | |
| Hydrochloric Acid SCHEMBL7832321 | 0.79 | ADRA2A (0.50) | AKR1C3KMT2AMEN1POLBLMNA | |
| SCHEMBL6398959 | 0.78 | AKR1C3 (0.56) | AKR1C3KMT2AMEN1POLBLMNA | |
| SCHEMBL22543772 | 0.77 | ESR1 (0.60) | AKR1C3KMT2AMEN1ESR1ESR2 | |
| SCHEMBL1946363 | 0.77 | AKR1C3 (0.55) | AKR1C3KMT2AMEN1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661918-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2021-10-14 | — | — | US | disclosed |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | RECURIUM IP HOLDINGS, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3661918-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D]PYRIMIDIN -3 - ONE ANALOGS | Recurium IP Holdings, LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2020-05-21 | — | — | US | disclosed |
| CN-111094253-A | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019028008-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS | Zeno Royalties & Milestones, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | AKR1C3 996/4885KMT2A 3525/4885MEN1 1662/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | AKR1C3 453/4885KMT2A 3405/4885MEN1 2033/4885 |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | AKR1C3 996/4885KMT2A 3525/4885MEN1 1662/4885 |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | MKI67, BRCA1, CCND1 | AKR1C3 1228/4885KMT2A 3070/4885MEN1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.